Publications in collaboration with researchers from Pfizer (United States) (29)

2024

  1. Airway and Blood Monocyte Transcriptomic Profiling Reveals an Antiviral Phenotype in Infants With Severe Respiratory Syncytial Virus Infection

    Journal of Infectious Diseases, Vol. 229, pp. S100-S111

2023

  1. Meningococcal Disease in the Post–COVID-19 Era: A Time to Prepare

    Infectious Diseases and Therapy

2022

  1. Age-Specific Estimates of Respiratory Syncytial Virus-Associated Hospitalizations in 6 European Countries: A Time Series Analysis

    Journal of Infectious Diseases, Vol. 226, pp. S29-S37

  2. Global Disease Burden of Respiratory Syncytial Virus in Preterm Children in 2019: A Systematic Review and Individual Participant Data Meta-Analysis Protocol

    Journal of Infectious Diseases, Vol. 226, pp. S135-S141

  3. Patient Involvement in RSV Research: Towards Patients Setting the Research Agenda

    Journal of Infectious Diseases, Vol. 226, pp. S130-S134

  4. Year-to-year variation in attack rates could result in underpowered respiratory syncytial virus vaccine efficacy trials

    Journal of Clinical Epidemiology, Vol. 147, pp. 11-20

2021

  1. Cappric study—characterization of community-acquired pneumonia in spanish adults managed in primary care settings

    Microorganisms, Vol. 9, Núm. 3, pp. 1-11

  2. Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus

    Nature Communications, Vol. 12, Núm. 1

  3. Global and regional burden of hospital admissions for pneumonia in older adults: A systematic review and meta-analysis

    Journal of Infectious Diseases, Vol. 222, pp. S570-S576

  4. Immunological and inflammatory biomarkers of susceptibility and severity in adult respiratory syncytial virus infections

    Journal of Infectious Diseases, Vol. 222, pp. S584-S591

  5. Publisher Correction: Distinct patterns of within-host virus populations between two subgroups of human respiratory syncytial virus (Nature Communications, (2021), 12, 1, (5125), 10.1038/s41467-021-25265-4)

    Nature Communications

  6. Review of clinical studies comparing meningococcal serogroup C immune responses induced by MenACWY-TT and monovalent serogroup C vaccines

    Human Vaccines and Immunotherapeutics, Vol. 17, Núm. 7, pp. 2205-2215

2020

  1. Protecting the most vulnerable age group: a review of MenACWY-TT immunogenicity and safety in infants

    Expert Review of Vaccines, Vol. 19, Núm. 4, pp. 313-325

2017

  1. Cardiovascular efficacy and safety of bococizumab in high-risk patients

    New England Journal of Medicine, Vol. 376, Núm. 16, pp. 1527-1539

  2. Circulating antibody 1 and 2 years after vaccination with the 13-valent pneumococcal conjugate vaccine in preterm compared with term infants

    Pediatric Infectious Disease Journal, Vol. 36, Núm. 3, pp. 326-332

2015

  1. 13-Valent pneumococcal conjugate vaccine (PCV13) in preterm versus term infants

    Pediatrics, Vol. 135, Núm. 4, pp. e876-e886

2014

  1. Evolving role of 13-valent pneumococcal conjugate vaccine in clinical practice

    Pediatric Infectious Disease Journal

  2. Pneumococcal vaccination in Europe: Schedule adherence

    Clinical Therapeutics, Vol. 36, Núm. 5

2013

  1. Evaluation of 13-valent pneumococcal conjugate vaccine and concomitant meningococcal group C conjugate vaccine in healthy infants and toddlers in Spain

    Vaccine, Vol. 31, Núm. 46, pp. 5486-5494

  2. Immune response to 13-valent pneumococcal conjugate vaccine with a reduced dosing schedule

    Vaccine, Vol. 31, Núm. 42, pp. 4765-4774